证券代码：301075 证券简称：多瑞医药 公告编号：2025-046 西藏多瑞医药股份有限公司 关于与关联方签署《补充协议》暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 （五）注册地址：南京市江宁区科学园乾德路 5 号 7 号楼（紫金 方山） 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 9 日召开第二届董事会第十五次会议和第二届监事会第十四次会议， 审议通过了《关于签署〈股权转让协议〉的议案》，同意公司与前沿 生物药业（南京）股份有限公司（以下简称"前沿生物"）、上海前沿 建瓴生物科技有限公司（以下简称"上海建瓴"）等相关方签订《股 权转让协议》。具体内容详见公司于 2024 年 10 月 11 日发布在巨潮资 讯网（www.cninfo.com.cn）的《关于签署〈股权转让协议〉的公告》 （公告编号：2024-084）。 根据公司资金使用计划，经友好协商，公司与前沿生物、上海建 瓴等相关方签署《补充协议》，主要对付款节点进行了调整，该事项 已于 2025 年 4 月 29 日经第二届董事会独 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-048 西藏多瑞医药股份有限公司 第二届监事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 西藏多瑞医药股份有限公司（以下简称"公司"）第二届监事会第 二十次会议通知于 2025 年 4 月 28 日以邮件、微信形式发出，经全体 监事一致同意于 2025 年 4 月 29 日在公司会议室以现场结合通讯表 决的方式召开。本次会议应出席监事 3 人，实际出席监事 3 人。本次 会议由监事会主席赵宏伟先生召集并主持。会议的召集和召开符合 《中华人民共和国公司法》《中华人民共和国证券法》等法律、行政 法规、部门规章、规范性文件及《公司章程》规定。经与会监事审议， 形成如下决议。 二、监事会会议审议情况 （一）审议通过《关于签署补充协议的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 表决结果：通过。 具体内容详见同日刊登在巨潮资讯网（www.cninfo.com.cn）的相 关公告。 前期公司与前沿生物药业（南京）股份有限公司（以下简称"前 沿 ...

Financial Performance - In 2024, the company achieved a revenue of CNY 240.63 million, a decrease of 28.02% compared to the previous year [2] - The net profit attributable to the parent company was CNY -62.67 million, a decline of 432.44% year-on-year [2] - The revenue breakdown includes: - Formulations: CNY 186.79 million - Intermediates: CNY 38.00 million - APIs and others: CNY 15.83 million [2] Factors Affecting Performance - Price linkage of drugs significantly impacted the formulation business, particularly the core product Sodium Acetate Ringer's Injection, due to policy changes like medical insurance cost control and volume-based procurement [2] - Increased R&D expenses for the new traditional Chinese medicine (TCM) product, Yifei Jisheng Granules, with R&D investment accounting for 15.38% of revenue and a growth of 54.21% in R&D costs [2] - High production costs for some intermediates due to initial production stages and high raw material costs, leading to negative gross margins [2] Market Strategy Adjustments - The company plans to adjust market strategies for Sodium Acetate Ringer's Injection by increasing efforts in non-public medical institutions and expanding market development outside of centralized procurement [3] - A diversification strategy is in place to reduce reliance on a single product, with a focus on accelerating the approval of new products in various therapeutic areas [3] R&D and Product Development - The company is focusing on the development of new products, including the approval of Amisulpride Injection and Sodium Bicarbonate Injection, to mitigate risks associated with a single product [5] - The R&D team is working on the Yifei Jisheng Granules, which has completed Phase II clinical trials and is moving towards Phase III [6] Integration and Synergy - The integration of acquired companies, Xinchengda and Sichuan Duorui, is progressing, with improvements in production processes and resource sharing in R&D [4] - The intermediate business revenue has increased by 927.66% year-on-year, indicating initial success from the vertical integration strategy [4] Industry Outlook - The global and Chinese peptide drug market is projected to grow at a CAGR of 8.9% and 16.4% respectively from 2020 to 2025, with the market size expected to reach USD 96 billion globally and USD 18.2 billion in China by 2025 [7] - The pharmaceutical manufacturing industry is crucial for national economic development and public health, with significant growth potential in the coming years [7]

Core Viewpoint - Duorui Pharmaceutical reported a significant decline in revenue for Q1 2025, primarily due to decreased sales of its main product, sodium acetate Ringer's injection, and increased R&D expenses from recent acquisitions [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 49.44 million yuan, a year-on-year decrease of 36.98% [1]. - R&D expenses for the same period were 5.83 million yuan, reflecting a year-on-year increase of 93.26% [1]. - For the year 2024, the total revenue was 241 million yuan, with sodium acetate Ringer's injection contributing 187 million yuan, accounting for 77.63% of total revenue [2]. R&D and Product Development - Over the past three years, the company has invested a total of 87.45 million yuan in R&D, indicating a commitment to exploring diverse growth and transformation paths [2][4]. - The company has a strong focus on R&D, with 75 technical staff members, representing 15.50% of total employees, and R&D expenses in 2024 amounting to 37.00 million yuan, which is 15.38% of total revenue [4]. - New products in the pipeline include amantadine injection and sodium bicarbonate injection, with the company also advancing the development of traditional Chinese medicine [3][7]. Strategic Acquisitions and Market Position - Duorui Pharmaceutical has made strategic acquisitions, including Xin Cheng Da in September 2023 and Sichuan Duorui in November 2024, to establish an integrated raw material and formulation development framework [3][5]. - The company aims to enhance its market position by expanding into the peptide raw material drug sector, with the peptide drug market in China projected to grow from 8.5 billion USD in 2020 to 18.2 billion USD by 2025 [5][6]. - The acquisition of a 70% stake in Shanghai Qianyan Biotechnology is expected to optimize resource allocation and diversify the company's development [5]. Industry Trends and Future Outlook - The pharmaceutical industry is experiencing increased regulatory standards and market concentration due to policies like "consistency evaluation of generic drugs" and "centralized procurement" [2]. - The company is focusing on high-end peptide raw materials and aims to enhance its production capabilities and market competitiveness through strategic acquisitions and R&D investments [6][7]. - Duorui Pharmaceutical plans to develop a dual-driven strategy combining chemical raw materials and formulations, while also responding to national policies encouraging the development of traditional Chinese medicine [7].

Core Viewpoint - Duorui Pharmaceutical (301075.SZ) reported its first annual loss since going public, with total revenue of 241 million yuan, a year-on-year decline of 28.02%, and a net profit attributable to shareholders of -62.67 million yuan, marking a staggering decline of 432.44% from profit to loss [2] Group 1: Financial Performance - The company's core product, sodium acetate Ringer's injection, which previously accounted for over 90% of revenue, saw sales plummet from 465 million yuan in 2021 to less than 120 million yuan in 2024, a nearly 50% year-on-year decline [3] - The decline in sales was primarily due to the product being selected in the 10th batch of national drug procurement, resulting in a significant drop in the bidding price [3] - Operating cash flow for 2024 was -67.18 million yuan, a drastic decrease of 641.19% year-on-year, mainly due to reduced sales revenue [6] Group 2: Strategic Challenges - The company is heavily reliant on a single core product, which exposes it to risks in a changing policy environment characterized by medical insurance cost control and normalized bulk procurement [3] - Duorui Pharmaceutical's acquisition of a 70% stake in Shanghai Jianling for 271 million yuan, which included debt compensation, is seen as a key move towards transforming into high-end raw materials, but the acquisition came with a high premium of 1182% [4] - The company’s cash reserves were significantly impacted by the acquisition, leaving only 110 million yuan in cash and equivalent, while short-term and long-term borrowings reached 25.02 million yuan and 18.8 million yuan, respectively [4] Group 3: R&D and Diversification Efforts - In an attempt to diversify revenue sources, the company has been exploring agency business and new drug development, with sales from its agency product, amoxicillin sodium and clavulanate potassium injection, reaching 19.57 million yuan, accounting for 13.01% of total revenue [6] - R&D investment increased by 54.21% in 2024 to 37.00 million yuan, representing 15.38% of revenue, but the low conversion efficiency is a concern, as the net profit excluding non-recurring items dropped by 1365.6% [6] - The company aims to accelerate the commercialization of intermediate and peptide raw material projects and develop derivatives of sodium acetate Ringer's injection, but the success of these strategies depends on the integration efficiency of acquired assets and the speed of new product pipeline development [7]

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.2000 | -0.0300 | -566.67 | -0.0300 | | 每股净资产（元） | 8.26 | 9.37 | -11.85 | 9.46 | | 每股公积金(元) | 6.34 | 6.36 | -0.31 | 6.37 | | 每股未分配利润(元) | 0.92 | 1.99 | -53.77 | 1.81 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.49 | 0.78 | -37.18 | 0.78 | | 净利润(亿元) | -0.16 | -0.03 | -433.33 | -0.02 | | 净资产收益率(%) | -2.33 | -0.33 | -606.06 | -0.32 | 前十大流通股东累计持有： 5740.13万股 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 西藏多瑞医药股份有限公司（以下简称"公司"）第二届监事会第 十九次会议通知于 2025 年 4 月 21 日以邮件、微信形式发出，并于 2025 年 4 月 24 日在公司会议室以现场结合通讯表决的方式召开。本 次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席 赵宏伟先生召集并主持。会议的召集和召开符合《中华人民共和国公 司法》《中华人民共和国证券法》等法律、行政法规、部门规章、规范 性文件及《公司章程》规定。经与会监事审议，形成如下决议。 二、监事会会议审议情况 （一）审议通过《2025 年第一季度报告》 证券代码：301075 证券简称：多瑞医药 公告编号：2025-043 西藏多瑞医药股份有限公司 第二届监事会第十九次会议决议公告 2025 年 4 月 25 日 三、备查文件 《第二届监事会第十九次会议决议》 特此公告。 西藏多瑞医药股份有限公司 监事会 经审议，监事会认为公司 2025 年第一季度报告内容真实、准确、 完整地反映了公司 2025 年第一季度经营的 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-040 西藏多瑞医药股份有限公司 第二届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西藏多瑞医药股份有限公司（以下简称"公司"）第二届董事会第 二十次会议通知于 2025 年 4 月 21 日以邮件、微信形式发出,并于 2025 年 4 月 24 日在公司会议室以现场结合通讯表决的方式召开。会议由 董事长邓勇先生主持。应出席董事 7 人，实际出席董事 7 人。董事以 现场或通讯方式出席本次会议，监事赵宏伟、王堂、周佳丽及高级管 理人员李超、韦文钢、黄志纯、敖博列席本次会议。会议的召集和召 开符合《中华人民共和国公司法》《中华人民共和国证券法》等法律、 行政法规、部门规章、规范性文件及《公司章程》规定。经与会董事 审议，形成如下决议。 二、董事会会议审议情况 （一）审议通过《2025 年第一季度报告》 经审议，公司 2025 年第一季度报告内容真实、准确、完整地反 映了公司 2025 年第一季度经营的实际情况，不存在任何虚假记载、 误导性陈述或 ...

西藏多瑞医药股份有限公司 2025 年第一季度报告 证券代码：301075 证券简称：多瑞医药 公告编号：2025-042 西藏多瑞医药股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经过审计 □是 否 1 西藏多瑞医药股份有限公司 2025 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 49,443,387.50 | 78,457,398.26 | -36.98% | | 归属于上市公司股东 ...